Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Margaret RosenfeldRon Gibson

Abstract

To describe the prevalence of the CF pathogens Pseudomonas aeruginosa, Staphylococcus aureus and Haemophilus influenzae in OP cultures from healthy children. Oropharyngeal (OP) swabs were collected from 100 healthy children ≤18 years of age undergoing a clinically indicated procedure. P. aeruginosa was isolated from the OP swab of one participant, S. aureus from 48 participants (including 4 methicillin-resistant) and H. influenzae from 47 participants. Cultures from 75 participants grew one or more of these organisms (55 grew one, 19 grew 2 and one grew 3 organisms). P. aeruginosa is rarely recovered from the oropharynx of healthy children ≤18 years of age, while recovery of S. aureus and H. influenzae is common. It is important to understand what the "normal" prevalence of CF pathogens is in the oropharynx in order to aid interpretation of OP cultures in CF patients.

References

Oct 7, 2004·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·M SinaasappelG Döring
Apr 11, 2009·Pediatric Pulmonology·David CarlsonBrian P O'Sullivan

❮ Previous
Next ❯

Citations

Jan 31, 2016·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Marco ZampoliBrenda Morrow
Apr 1, 2015·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Danieli Barino SalinasMartin Kharrazi
Nov 26, 2015·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·A GenevoisM Mittaine
Sep 22, 2015·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Michael DoumitAdam Jaffe
Jul 16, 2014·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Lisa SaimanDavid J Weber
Jul 23, 2016·Genetic Testing and Molecular Biomarkers·Danieli Barino SalinasRichard B Parad
Dec 13, 2016·American Journal of Respiratory and Critical Care Medicine·Sanja StanojevicFelix A Ratjen
Aug 17, 2018·Current Opinion in Pulmonary Medicine·Matthew N Hurley, Alan R Smyth
Jan 19, 2019·Annals of the American Thoracic Society·Dave P NicholsNicole Mayer-Hamblett
Jan 10, 2020·Pediatric Pulmonology·Anne MunckUNKNOWN DPAM Study Group
Dec 3, 2016·American Journal of Respiratory and Critical Care Medicine·Sarath C RanganathanUNKNOWN Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF)
Oct 17, 2017·Annals of the American Thoracic Society·Matthew N HurleyAlan R Smyth
Jul 1, 2021·NPJ Systems Biology and Applications·Alina Renz, Andreas Dräger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.